Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics
This article was originally published in The Pink Sheet Daily
Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.
You may also be interested in...
Several anti-obesity treatments are in the home stretch of late-stage development, promising to rev up a stagnant market and satisfy pent-up demand. But there's an elephant in the weight loss room - nobody seems to know who will pick up the tab for new drugs
Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan